Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Xevinapant by Merck for Nasopharyngeal Cancer: Likelihood of Approval
Xevinapant is under clinical development by Merck and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...